Table of Contents
Outcomes-Based Pharmaceutical Pricing' s three chapters contain process,
structure and resource data collected from 30 pharmaceutical and biotechnology
companies.
Key metrics include the following:
- Share of companies that have a dedicated department dedicated to driving
pricing strategy - also broken down by company size
- Internal stakeholders that influence pricing efforts
- Cross-functional involvement in strategic pricing decisions
- Number of pricing studies conducted by phase, innovative versus me-too
drugs
- Pricing staff support by phase of development, innovative versus me-too
drugs
- Top criteria for determining product price: share of companies that rated
each as most important
- Share of companies whose revenues have been eroded by parallel trade and
re-importation
- Phase of development at which companies begin pricing research
- Effectiveness rating for pricing study types from 1 to 5
- Lifecycle entry and exit points for various functions involved in pricing
- Budget breakdown, by region and by company size
- 2008 pricing department headcount, by company size
- 2008 average headcount, by territory
- Global 2008 pricing budgets, by company size
- Groups that contribute funding to pricing
- Share of pricing budget that goes toward overhead expenses
- Expense ranges for a typical pricing study, by company size
| 
View Cart
